接受VV ECMO患者的输血实践(PROTECMO):一项前瞻性、多中心、观察性研究
PROTECMO是一项在41个ECMO中心开展的多中心前瞻性队列研究,纳入604例接受VV ECMO的ARDS成人患者。研究监测每日血红蛋白浓度及输血时的血红蛋白值,发现ECMO期间平均血红蛋白为9.1 g/dL,31%的ECMO日进行了输血,83%患者至少接受1单位红细胞。输血前平均血红蛋白为8.1 g/dL。时间依赖Cox模型显示,血红蛋白低于7 g/dL与ICU死亡风险升高相关(HR 2.99),而仅在血红蛋白低于7 g/dL时输血与死亡风险降低相关(HR 0.15),其他血红蛋白水平输血未见显著降低死亡。
要点
- 604例VV ECMO患者中,83%至少接受1单位红细胞,31%的ECMO日进行了输血。
- ECMO期间平均血红蛋白为9.1 g/dL,北美和高容量中心血红蛋白浓度更低。
- 输血前平均血红蛋白为8.1 g/dL,但随输血临床理由而异。
- 血红蛋白低于7 g/dL与ICU死亡风险升高相关(HR 2.99,95%CI 1.95-4.60)。
- 仅在血红蛋白低于7 g/dL时输血与ICU死亡风险降低相关(HR 0.15,95%CI 0.03-0.74),其他血红蛋白水平输血未报告显著降低死亡。
适用人群与场景
- 纳入:接受VV ECMO的急性呼吸窘迫综合征(ARDS)连续成人患者。
- 排除:年龄小于18岁、需要时无法提供知情同意、ECMO停留时间小于24小时的患者。
- 场景:41个ECMO中心(欧洲、北美、亚洲和澳大利亚)的VV ECMO成人患者。
研究设计与关键结果
- 研究类型:多中心、前瞻性、队列研究;41个ECMO中心;2018年12月1日至2021年2月22日纳入604例患者(431例[71%]男性,173例[29%]女性;平均年龄50岁[SD 13.6];插管时平均血红蛋白浓度10.9 g/dL[2.4])。
- 共7944个ECMO日,平均血红蛋白浓度9.1 g/dL(1.2),北美和高容量中心浓度更低。
- 2432个ECMO日(31%)进行了红细胞输注,504例(83%)患者至少接受1单位红细胞。
- 总体平均输血前血红蛋白浓度8.1 g/dL(1.1),但随输血临床理由而异。
- 时间依赖Cox模型:血红蛋白低于7 g/dL与其他较高血红蛋白浓度相比,与ICU死亡风险升高相关(HR 2.99[95%CI 1.95-4.60])。
- 红细胞输注仅在血红蛋白低于7 g/dL时与死亡风险降低相关(HR 0.15[0.03-0.74]);其他血红蛋白水平(7.0-7.9 g/dL、8.0-9.9 g/dL、高于10 g/dL)输血未报告显著降低死亡率。
证据类型、等级与局限
- 证据类型:多中心前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论:VV ECMO期间输血无普遍接受的阈值,但仅在血红蛋白低于7 g/dL时输血与较低死亡率相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In patients receiving venovenous (VV) extracorporeal membrane oxygenation (ECMO) packed red blood cell (PRBC) transfusion thresholds are usually higher than in other patients who are critically ill. Available guidelines suggest a restrictive approach, but do not provide specific recommendations on the topic. The main aim of this study was, in a short timeframe, to describe the actual values of haemoglobin and the rate and the thresholds for transfusion of PRBC during VV ECMO.
METHODS: PROTECMO was a multicentre, prospective, cohort study done in 41 ECMO centres in Europe, North America, Asia, and Australia. Consecutive adult patients with acute respiratory distress syndrome (ARDS) who were receiving VV ECMO were eligible for inclusion. Patients younger than 18 years, those who were not able to provide informed consent when required, and patients with an ECMO stay of less than 24 h were excluded. Our main aim was to monitor the daily haemoglobin concentration and the value at the point of PRBC transfusion, as well as the rate of transfusions. The practice in different centres was stratified by continent location and case volume per year. Adjusted estimates were calculated using marginal structural models with inverse probability weighting, accounting for baseline and time varying confounding.
FINDINGS: Between Dec 1, 2018, and Feb 22, 2021, 604 patients were enrolled (431 [71%] men, 173 [29%] women; mean age 50 years [SD 13·6]; and mean haemoglobin concentration at cannulation 10·9 g/dL [2·4]). Over 7944 ECMO days, mean haemoglobin concentration was 9·1 g/dL (1·2), with lower concentrations in North America and high-volume centres. PRBC were transfused on 2432 (31%) of days on ECMO, and 504 (83%) patients received at least one PRBC unit. Overall, mean pretransfusion haemoglobin concentration was 8·1 g/dL (1·1), but varied according to the clinical rationale for transfusion. In a time-dependent Cox model, haemoglobin concentration of less than 7 g/dL was consistently associated with higher risk of death in the intensive care unit compared with other higher haemoglobin concentrations (hazard ratio [HR] 2·99 [95% CI 1·95-4·60]); PRBC transfusion was associated with lower risk of death only when transfused when haemoglobin concentration was less than 7 g/dL (HR 0·15 [0·03-0·74]), although no significant effect in reducing mortality was reported for transfusions for other haemoglobin classes (7·0-7·9 g/dL, 8·0-9·9 g/dL, or higher than 10 g/dL).
INTERPRETATION: During VV ECMO, there was no universally accepted threshold for transfusion, but PRBC transfusion was invariably associated with lower mortality only when done with haemoglobin concentration of less than 7 g/dL.
FUNDING: Extracorporeal Life Support Organization.
参考来源
- Martucci G, Schmidt M, Agerstrand C, et al. Transfusion practice in patients receiving VV ECMO (PROTECMO): a prospective, multicentre, observational study. Lancet Respir Med. 2022. PMID: 36240836. doi:10.1016/S2213-2600(22)00353-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。